San Diego-dependent Viking Therapeutics marked itself as a significant competitor during the weight loss drug sector in February just after revealing promising information from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection and in March the comp